Thalys Medical Technology Group Inc. (603716.SS)
CNY 9.69
(-3.77%)
CNY 9.69
(-3.77%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 596.75 Million CNY | 6.73% |
| 2022 | 559.11 Million CNY | -30.01% |
| 2021 | 798.85 Million CNY | 13.53% |
| 2020 | 703.63 Million CNY | 1307.28% |
| 2019 | 50 Million CNY | 430.52% |
| 2018 | 9.42 Million CNY | -66.67% |
| 2017 | 28.27 Million CNY | 41.37% |
| 2016 | 20 Million CNY | 423.9% |
| 2015 | 3.81 Million CNY | -83.15% |
| 2014 | 22.65 Million CNY | 16.18% |
| 2013 | 19.5 Million CNY | -15.59% |
| 2012 | 23.1 Million CNY | 958.51% |
| 2011 | 2.18 Million CNY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 582.54 Million CNY | 1.58% |
| 2024 Q3 | 583.94 Million CNY | 0.23% |
| 2024 Q1 | 605.26 Million CNY | 1.71% |
| 2023 Q1 | 569.81 Million CNY | 1.91% |
| 2023 FY | 596.75 Million CNY | 6.73% |
| 2023 Q4 | 596.75 Million CNY | 1.55% |
| 2023 Q3 | 587.62 Million CNY | 0.82% |
| 2023 Q2 | 582.81 Million CNY | 2.28% |
| 2022 Q4 | 559.11 Million CNY | -9.18% |
| 2022 Q3 | 615.6 Million CNY | 6.16% |
| 2022 Q1 | 797.36 Million CNY | -0.19% |
| 2022 Q2 | 579.87 Million CNY | -27.28% |
| 2022 FY | 559.11 Million CNY | -30.01% |
| 2021 Q2 | 864.41 Million CNY | 6.66% |
| 2021 Q3 | 875.56 Million CNY | 1.29% |
| 2021 Q4 | 798.85 Million CNY | -8.76% |
| 2021 Q1 | 810.47 Million CNY | 15.18% |
| 2021 FY | 798.85 Million CNY | 13.53% |
| 2020 Q1 | 230 Million CNY | 360.0% |
| 2020 FY | 703.63 Million CNY | 1307.28% |
| 2020 Q3 | 675.1 Million CNY | 193.52% |
| 2020 Q2 | 230 Million CNY | 0.0% |
| 2020 Q4 | 703.63 Million CNY | 4.23% |
| 2019 FY | 50 Million CNY | 430.52% |
| 2019 Q4 | 50 Million CNY | 41707.07% |
| 2019 Q3 | 119.59 Thousand CNY | -98.73% |
| 2019 Q2 | 9.42 Million CNY | -33.33% |
| 2019 Q1 | 14.13 Million CNY | 50.0% |
| 2018 Q2 | 43.56 Million CNY | -0.68% |
| 2018 Q1 | 43.86 Million CNY | 55.13% |
| 2018 Q3 | 18.84 Million CNY | -56.73% |
| 2018 FY | 9.42 Million CNY | -66.67% |
| 2018 Q4 | 9.42 Million CNY | -50.0% |
| 2017 Q3 | 48.27 Million CNY | 141.37% |
| 2017 FY | 28.27 Million CNY | 41.37% |
| 2017 Q4 | 28.27 Million CNY | -41.43% |
| 2017 Q2 | 20 Million CNY | 0.0% |
| 2017 Q1 | 20 Million CNY | 0.0% |
| 2016 Q1 | - CNY | -100.0% |
| 2016 FY | 20 Million CNY | 423.9% |
| 2016 Q4 | 20 Million CNY | 456.72% |
| 2016 Q2 | 7.35 Million CNY | 0.0% |
| 2016 Q3 | 3.59 Million CNY | -51.17% |
| 2015 Q4 | 3.81 Million CNY | 0.0% |
| 2015 FY | 3.81 Million CNY | -83.15% |
| 2014 FY | 22.65 Million CNY | 16.18% |
| 2013 FY | 19.5 Million CNY | -15.59% |
| 2012 FY | 23.1 Million CNY | 958.51% |
| 2011 FY | 2.18 Million CNY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 1.1 Billion CNY | 45.879% |
| Joinn Laboratories(China)Co.,Ltd. | 41.92 Million CNY | -1323.4% |
| WuXi AppTec Co., Ltd. | 687.01 Million CNY | 13.138% |
| Autobio Diagnostics Co., Ltd. | 24.63 Million CNY | -2322.317% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 267.61 Million CNY | -122.992% |
| Chemclin Diagnostics Co., Ltd. | 227.94 Million CNY | -161.793% |